Louvain-la-Neuve, Belgium August 18, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces it has signed a collaboration agreement with Apollo Hospitals Enterprise Ltd (AHEL), to provide proton therapy training and education programs for IBA customers in Asia.
AEHL is a long-term customer of IBA, purchasing a Proteus®PLUS proton therapy system in 2013 and successfully utilizing it in the treatment of cancer patients for more than three years. Since AHEL started its proton therapy operations at Apollo Proton Cancer Centres (APCC), it has gained significant expertise and experience in treating a wide range of tumor types IBA plans to leverage this experience, working with AEHL to provide a training and education program initiative, to aspiring proton therapy users in Asia and other parts of the world.
Olivier Legrain, Chief Executive Officer at IBA, said: “Over recent years, Apollo Hospitals has shown its expertise and enthusiasm by successfully organizing training symposia for the local and international proton therapy experts’ community. We look forward to collaborating with Apollo in order to provide high-quality training and education to our customers and prospects in Asia without them traveling to another continent.”
Dr. Prathap C Reddy, Founder and Chairman of Apollo Hospitals Enterprise Ltd, said: “An acute need for high-quality cancer care, coupled with an increasing prevalence of cancer cases in India, led to the creation of Apollo Cancer Centres (ACC) around three decades ago. Since then, ACC has continually introduced the finest and most advanced cancer care into India, with the most recent being bringing Proton Therapy to the region. Furthermore, in keeping with its resolute mission to raise the bar in cancer care for all in need, in association with IBA, the Apollo Proton Cancer Centre will be the first of its kind training and education program reference centre in Asia.”
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.